Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.
about
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complexMechanisms of evasive resistance to anti-VEGF therapy in glioblastomaPros and cons of current brain tumor imagingLPS alters the immuno-phenotype of glioma and glioma stem-like cells and induces in vivo antitumor immunity via TLR4Bevacizumab at recurrence in high-grade glioma.Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging studyRelevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteriaIncidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis.The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular CarcinomaEfficacy of salvage stereotactic radiotherapy for recurrent glioma: impact of tumor morphology and method of target delineation on local controlBevacizumab for the treatment of glioblastoma.Novel chemotherapeutics and other therapies for treating high-grade glioma.Advanced interstitial chemotherapy for treating malignant glioma.Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis.Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas.Discrepant MR and [(18)F]Fluoroethyl-L-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure.Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas.Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.Generation of neuronal progenitor cells in response to tumors in the human brain.Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis.Increased invasion of malignant gliomas after 15-LO-1 and HSV-tk/ganciclovir combination gene therapy."Paradoxical" findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab.Sustainable release of carmustine from biodegradable poly[((D,L))-lactide-co-glycolide] nanofibrous membranes in the cerebral cavity: in vitro and in vivo studies.Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme.
P2860
Q24293027-F457DAF4-8217-4554-A73B-6AB1BB41EE84Q27021470-B7A58E3B-0DD8-46D4-8F05-E80D8C06CB5DQ30860126-6DF98A9A-C748-47E8-B6CE-C6B7DC33F8D1Q33824394-45D67FFA-0E68-4A78-8F01-0204CDAC94C4Q34045979-BBA09C7D-9982-462B-ACB9-04E9E76B03E0Q35570253-7FB1BBB1-C2C5-4D49-8E7F-4352D6051C95Q35696386-379AAB52-8F5B-4759-BC4B-EF1F87B488BDQ36361484-977870BB-E6E5-4784-AFD4-A41637F5390FQ36833480-BE9DC2A8-71BC-4683-8989-2B1FE72E88C2Q36867831-ACF231ED-79B8-416C-A266-1EB27E5A0EFFQ37245796-4A98F7BA-ECCD-49A0-9CD5-94C046660B47Q37481209-F0542374-511C-431D-974C-D8ED228D13ECQ38129428-FC9070CC-32B9-4A89-888A-620FFCC20475Q38569802-6B7FEA24-DE4D-4BDB-83F0-F4E6DAD9CA04Q38849948-108E6AED-D50F-4937-884F-7105ADB50A6CQ39799485-E6211E63-F09F-4EF9-8163-95030645C7B6Q40333907-1E257996-AA06-4BD8-B980-A098B69F5ECCQ40886583-39F14E29-8E84-48A7-93C6-BDDF8DE7A8C2Q41904258-2F5E3ABE-037C-4686-B346-42D69A0153F2Q44000754-17ADB6F3-9907-4A44-B638-10BF05A11A96Q44461998-2E6C6086-45B0-4201-9B59-60DC10374B41Q44569108-F005C5E5-8FD2-403F-9ED4-67F31CD87D2FQ44661518-16EC1D77-0834-4BFB-A7C6-771A32597B58Q45882637-84172DED-AFC4-497F-AFA3-99C8C26D3598Q47105371-722C3B16-B046-4556-861F-44594173B0A7Q48225434-C06E3B21-70E3-44C1-B8CD-29C757EE0D33Q48673902-4F2B067D-BF85-4B42-A966-3A3275E90CFC
P2860
Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Patterns of progression in mal ...... apy: perceptions and evidence.
@ast
Patterns of progression in mal ...... apy: perceptions and evidence.
@en
type
label
Patterns of progression in mal ...... apy: perceptions and evidence.
@ast
Patterns of progression in mal ...... apy: perceptions and evidence.
@en
prefLabel
Patterns of progression in mal ...... apy: perceptions and evidence.
@ast
Patterns of progression in mal ...... apy: perceptions and evidence.
@en
P2860
P1476
Patterns of progression in mal ...... apy: perceptions and evidence.
@en
P2093
Antje Wick
Markus Weiler
P2860
P2888
P304
P356
10.1007/S11910-011-0184-0
P577
2011-06-01T00:00:00Z
P6179
1005014853